Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 11974 results found since Jan 2013.
Diseases of the Coronary Microcirculation: Diagnosis and Treatment
CONCLUSION: Approximately 25% of patients with CMD have symptoms that do not respond to intensive treatment with the currently available modalities. New treatments, including interventional therapies, are being studied. Their long-term benefit remains to be assessed and compared to that of the existing methods.PMID:37721132 | DOI:10.3238/arztebl.m2023.0205
Source: Deutsches Arzteblatt International - September 18, 2023 Category: General Medicine Authors: Helen Ullrich-Daub Steffen Daub Maximilian Olschewski Thomas M ünzel Tommaso Gori Source Type: research
Nurse Practitioner Care Compared to Primary Care or Nephrologist Care in Early CKD
CONCLUSIONS: Nurse practitioner care for patients with CKD was associated with better guideline-concordant care than primary care alone or nephrologist care, with clinical outcomes that were better than or equivalent to primary care alone, and similar to those with care by nephrologists.PMID:37721865 | DOI:10.2215/CJN.0000000000000305
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 18, 2023 Category: Urology & Nephrology Authors: Matthew T James Tayler D Scory Ellen Novak Braden J Manns Brenda R Hemmelgarn Aminu K Bello Pietro Ravani Bhavneet Kahlon Jennifer M MacRae Paul E Ronksley Source Type: research
Atherosclerosis as a Risk Factor for IBD: A Population-Based Case-Control Study
CONCLUSIONS: A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.PMID:37721310 | DOI:10.14309/ajg.0000000000002502
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Adam S Faye Jordan Axelrad Jiangwei Sun Jonas Halfvarson Jonas S öderling Ola Ol én Jonas F Ludvigsson Source Type: research
Nurse Practitioner Care Compared to Primary Care or Nephrologist Care in Early CKD
CONCLUSIONS: Nurse practitioner care for patients with CKD was associated with better guideline-concordant care than primary care alone or nephrologist care, with clinical outcomes that were better than or equivalent to primary care alone, and similar to those with care by nephrologists.PMID:37721865 | DOI:10.2215/CJN.0000000000000305
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 18, 2023 Category: Urology & Nephrology Authors: Matthew T James Tayler D Scory Ellen Novak Braden J Manns Brenda R Hemmelgarn Aminu K Bello Pietro Ravani Bhavneet Kahlon Jennifer M MacRae Paul E Ronksley Source Type: research
Pravastatin for lowering lipids
CONCLUSIONS: Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo-controlled trials.PMID:37721222 | PMC:PMC10506175 | DOI:10.1002/14651858.CD013673.pub2
Source: Cochrane Database of Systematic Reviews - September 18, 2023 Category: General Medicine Authors: Stephen P Adams Nima Alaeiilkhchi Sara Tasnim James M Wright Source Type: research
Diseases of the Coronary Microcirculation: Diagnosis and Treatment
CONCLUSION: Approximately 25% of patients with CMD have symptoms that do not respond to intensive treatment with the currently available modalities. New treatments, including interventional therapies, are being studied. Their long-term benefit remains to be assessed and compared to that of the existing methods.PMID:37721132 | DOI:10.3238/arztebl.m2023.0205
Source: Deutsches Arzteblatt International - September 18, 2023 Category: General Medicine Authors: Helen Ullrich-Daub Steffen Daub Maximilian Olschewski Thomas M ünzel Tommaso Gori Source Type: research
Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis
CONCLUSION: Bone-targeting nanoparticles incorporating functionalized simvastatin can target bone. Thus, in order to distribute simvastatin subcutaneously for the treatment of osteoporosis, the developed nanoparticles may act as a promising approach.PMID:37718521 | DOI:10.2174/1389450124666230915092910
Source: Current Drug Targets - September 18, 2023 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Amarjot Kaur Grewal Samrat Chauhan Chander Parkash Dora Thakur Gurjeet Singh Source Type: research
Diseases of the Coronary Microcirculation: Diagnosis and Treatment
CONCLUSION: Approximately 25% of patients with CMD have symptoms that do not respond to intensive treatment with the currently available modalities. New treatments, including interventional therapies, are being studied. Their long-term benefit remains to be assessed and compared to that of the existing methods.PMID:37721132 | DOI:10.3238/arztebl.m2023.0205
Source: Deutsches Arzteblatt International - September 18, 2023 Category: General Medicine Authors: Helen Ullrich-Daub Steffen Daub Maximilian Olschewski Thomas M ünzel Tommaso Gori Source Type: research
Efficacy of a novel glioma therapy based on ferroptosis induced by layered double hydroxide loaded with simvastatin
In this study, folic acid (FA)-modified layered double hydroxide loaded with simvastatin (SIM), a ferroptosis drug, was used to prepare a novel ferroptosis nanodrug (FA-LDH@SIM). The prepared nanodrug improved the therapeutic effect of SIM on glioma. Compared with free SIM, FA-LDH@SIM showed greater cytotoxicity, significantly inhibited glioma cell proliferation, and significantly inhibited glioma invasion and migration ability. Furthermore, SIM could induce changes in certain ferroptosis indicators, including increased intracellular LPO, ROS and MDA level, decreased GSH production, increased divalent iron level, and chang...
Source: Environmental Research - September 17, 2023 Category: Environmental Health Authors: Wei Peng Yufeng Qian Xuchen Qi Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
2023 Chinese guideline for lipid management
Front Pharmacol. 2023 Aug 29;14:1190934. doi: 10.3389/fphar.2023.1190934. eCollection 2023.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respe...
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Jian-Jun Li Shui-Ping Zhao Dong Zhao Guo-Ping Lu Dao-Quan Peng Jing Liu Zhen-Yue Chen Yuan-Lin Guo Na-Qiong Wu Sheng-Kai Yan Zeng-Wu Wang Run-Lin Gao Source Type: research
